טוען...
The impact of celecoxib on outcomes in advanced prostate cancer patients undergoing androgen deprivation therapy
Recent work suggests the selective Cox-2 inhibitor celecoxib delays progression to androgen independence in hormone sensitive prostate cancer (HSPC) through inhibition of the androgen receptor (AR) and ErbB signaling. However, human studies examining its effect on delaying disease progression while...
שמור ב:
| הוצא לאור ב: | Am J Clin Exp Urol |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
e-Century Publishing Corporation
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6055075/ https://ncbi.nlm.nih.gov/pubmed/30038944 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|